Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents Awarded to Alnylam, GE Healthcare, Sanofi, and More

Premium

Title: Treatment of Cancer by Inhibition of IGFBPs and Clusterin

Patent Number: 8,835,401

Filed: May 29, 2013

Inventor: Martin Gleave, University of British Columbia


Title: Expression Cassettes for Seed-specific Expression in Plants

Patent Number: 8,835,622

Filed: Nov. 25, 2009

Lead Inventor: Franck Pinot, Bayer BioScience


Title: RNA Interference-mediated Inhibition of Catenin Beta 1 Gene Expression Using Short Interfering Nucleic Acid

Patent Number: 8,835,623

Filed: Aug. 6, 2013

Lead Inventor: Duncan Brown, Sirna Therapeutics (Alnylam Pharmaceuticals)


Title: microRNA Scaffolds, Non-naturally Occurring microRNAs, and Methods for Optimizing Non-naturally Occurring microRNAs

Patent Number: 8,841,267

Filed: May 22, 2008

Lead Inventor: Melissa Kelley, Dharmacon (GE Healthcare)


Title: Polynucleotides for Use in Treating and Diagnosing Cancers

Patent Number: 8,841,269

Filed: Feb. 23, 2011

Inventor: Gary Xiao, Creighton University


Title: Use of Inhibitors of Zdhhc2 Activity for Modulation of Adipogenesis

Patent Number: 8,841,270

Filed: May 19, 2010

Lead Inventor: Diana Hall, Sanofi


Title: Double-stranded RNA-based Nanoparticles for Insect Gene Silencing

Patent Number: 8,841,272

Filed: May 31, 2012

Lead Inventor: Kun Yan Zhu, Kansas State University


Title: Precursor miRNA Loop-modulated Target Regulation

Patent Number: 8,841,437

Filed: May 28, 2010

Lead Inventor: Chang-Zheng Chen, Stanford University

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.